Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:37:36.858Z.
Consensus retrieved: 2026-10-06T12:52:17.846Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:37:36.858Z.
Quote observation: 2026-10-06T16:35:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c19c85bab9715eb02e93ed72e58c77cc0b51866a8f8130ffbf7fdbc9ca61d83e
Forward PE Ratio (N/A) = Dated Quote Price ($44.19) / Consensus Forward EPS ($-3.60)
FORWARD PE RATIO
N/A
Ionis Pharmaceuticals, Inc.
Market Cap
$7.34B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Ionis Pharmaceuticals, Inc. (IONS) | $7.34B | N/A |
| Hinge Health, Inc. (HNGE)vs › | $7.61B | 42.39 |
| Cytokinetics, Incorporated (CYTK)vs › | $7.65B | N/A |
| HealthEquity, Inc. (HQY)vs › | $7.66B | 19.40 |
| Alkermes plc (ALKS)vs › | $7.01B | N/A |
| Praxis Precision Medicines, Inc. (PRAX)vs › | $7.73B | N/A |
| Caris Life Sciences, Inc. (CAI)vs › | $7.92B | 241.40 |
| Chemed Corporation (CHE)vs › | $6.67B | 20.02 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.60B | N/A |
| Immunovant, Inc. (IMVT)vs › | $6.60B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $44.19, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.60 | $-3.67 – $-3.56 | 11 | n/m |
| 2027-12-31 | $-2.04 | $-2.99 – $-1.29 | 11 | n/m |
| 2028-12-31 | $0.19 | $-2.49 – $2.62 | 14 | 228.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
